Diabetes mellitus comorbidity in patients enrolled in tuberculosis drug efficacy trials around the world: A systematic review

Abstract

Aims With a prevalence of 16%, diabetes mellitus (DM) is one of the most frequent non‐communicable comorbidities of tuberculosis (TB). DM is a major risk factor for adverse TB outcomes and may require personalized TB drug dosing regimens. However, information on the inclusion of DM in TB drug trials is lacking. We aimed to assess the percentage of recent TB drug efficacy trials that included DM patients. Methods A systematic review was performed and reported according to PRISMA guidelines. PubMed, Science Direct, and http://ClinicalTrials.gov databases were systematically searched for TB drug trials published between 1 January 2012 and 12 September 2017. Primary outcome was the percentage of TB drug trials performed around the world that included DM patients. Results Out of the included 41 TB drug trials, 12 (29.3%) reported DM comorbidity among the study participants. Nine trials (21.9%) excluded all patients with DM comorbidity, ten (24.4%) excluded only insulin‐dependent or uncontrolled DM, and 10 (24.4%) did not mention whether DM was included or excluded. Of the 12 trials that included DM comorbidity, the majority did not report the diagnostic criteria for DM and none reported outcomes in the DM subpopulation. Inclusion of DM was higher in drug‐resistant‐TB trials (67%, P = .003, vs drug‐susceptible) and trials performed in Asia (60%, P = .006, vs Africa). Conclusions Fewer than 1/3 recent TB drug trials reported the inclusion of DM. To better reflect real‐world DM prevalence and differential TB drug effectiveness, inclusion of DM patients requires increased attention for future TB drug trials.

Interim Effectiveness and Safety Comparison of Bedaquiline-Containing Regimens for Treatment of Diabetic Versus Non-Diabetic MDR/XDR-TB Patients in China: A Multicenter Retrospective Cohort Study

“…In China, which shoulders a double burden of DM and MDR-TB cases, numbers of patients with DM reached 116.4 million in 2019, ranking first in DM prevalence worldwide [1], while estimated MDR/RR-TB prevalence reached 66,000, ranking second worldwide [2]. Notably, DM is a major risk factor for progression of latent TB to active TB; DM triples future active TB risk and doubles future MDR-TB risk [3][4][5]. Several studies have shown that DM negatively impacts treatment outcomes in patients with MDR-TB.…”

A retrospective study on Tuberculous Lymphadenitis; A retrospective finding from multicenters referal hospitals

“…Diabetes, Human Immuno deficiency virus and Hepatitis were studied and it shows no statistically significant result to any of the risk factors. Recently study performed in North-East Peninsular Malaysia on the mortality among the Tb and HIV co-morbid patients reported strong relationship on the unsuccessful treatment outcomes of TB and a major risk factor for extra-pulmonary Tb [16]. Present study findings shows only few patients were found to have diabetes which is less than 15 percent of the total diagnosed population with Tb lymphadenitis.…”

BCG and BCGΔBCG1419c protect type 2 diabetic mice against tuberculosis via different participation of T and B lymphocytes, dendritic cells and pro-inflammatory cytokines

“…Furthermore, T2D favors more severe manifestations of TB as compared with those occurring in patients without T2D 11 , including extended lung damage especially at chronic stages of the comorbidity 12,13 . Despite this, the evaluation of new treatments or preventive measures against TB in the context of T2D constitutes a poorly explored area 14 , with no report available as of today about the efficacy of protection of any vaccine candidate against TB in the context of T2D.…”